Amplification of tumor antigen presentation by NLGplatin to improve chemoimmunotherapy

Publication date: Available online 19 November 2019Source: International Journal of PharmaceuticsAuthor(s): Yong Zhu, Lei Xing, Xiao Zheng, Chen-Xi Yang, Yu-Jing He, Tian-Jiao Zhou, Qing-Ri Jin, Hu-Lin JiangAbstractOxaliplatin is a chemotherapeutic agent widely used in cancer treatment whereas its immunosuppressive effect hinders the progress of immunotherapy. Here we have synthesized a new compound NLGplatin constructed by combining oxaliplatin (OXA) and indoleamine 2,3-dioxygenase (IDO) inhibitor NLG919. The NLGplatin acquires chemotherapeutic properties of OXA and can activate the immune system, and also retains the ability to inhibit IDO enzyme activity without affecting the proliferation of immune cells. This difunctional drug has a great potential to achieve effective cancer chemoimmunotherapy.Graphical abstractThe NLGplatin synthesized by combining oxaliplatin (OXA) and indoleamine 2,3-dioxygenase (IDO) inhibitor NLG919 retains the anti-tumor activity and the ability to inhibit IDO enzyme.
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research